Journal Basic Info
- Impact Factor: 0.285**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558
Major Scope
- Asthma
- Dermatology and Cosmetology
- Chronic Disease
- Epilepsy and Seizures
- Family Medicine and Public Health
- Inflammation
- Urology Cases
- Physical Medicine & Rehabilitation
Abstract
Citation: Clin Case Rep Int. 2021;5(1):1226.DOI: 10.25107/2638-4558.1226
The Administration of Tocilizumab to a COVID-19 Patient with Psoriasis Vulgaris – A Case Report
Marija Branković, Igor Jovanović , Tijana Radonjić , Ilija Bukurecki and Marija Zdravković
University Hospital Medical Center Bezanijska Kosa, Serbia University of Belgrade, Serbia
*Correspondance to: Marija Branković
PDF Full Text Case Report | Open Access
Abstract:
A case of male patient admitted to a hospital with bilateral pneumonia caused by COVID-19 is presented. It was found on admission that the patient had had psoriasis vulgaris; the patient had no therapy for six years and he had no regular checkups. Due to progression and high CT scan severity score and elevated serum IL-6, the decision was made to administer the patient tocilizumab. Upon administration, psoriatic lesions were in retreat. Even though there are some reports describing tocilizumab induced psoriasis, some studies have demonstrated a high level of IL-6 in psoriatic plaques. Therefore, therapies that disrupt IL-6 signaling could be a treatment option for psoriasis.
Keywords:
Covid-19; Covid; Corona Virus; Coronavirus disease 2019
Cite the Article:
Branković M, Jovanović I, Radonjić T, Bukurecki I, Zdravković M. The Administration of Tocilizumab to a COVID-19 Patient with Psoriasis Vulgaris – A Case Report. Clin Case Rep Int. 2021; 5: 1226..